Legislation that cleared the US House 4 February would support a drug supply chain "elasticity" pilot project to show how critical supplies could expand when demand soars like it has with the COVID-19 pandemic, and then shrink back afterward. While the initiative is designated as a pilot, it would receive significant funding: $1.5bn.
US Supply Chain "Elasticity" Pilot Would Get Major Funds In House-Passed Legislation
COMPETES Act also includes enhanced penalties for drug makers who falsify or destroy records, power for the FDA to recall harmful drugs, funding for drug manufacturing technology and additional supply chain flexibility efforts.
More from Distribution/Supply Chain
More from Compliance
• By
Amid ongoing generic drug supply problems, Japan's government is to set up a new fund to support corporate investments geared towards manufacturing and consolidation.
• By
Pharma executives and investors are waiting with bated breath to find out if President Trump will include drugs in a new round of tariffs to be announced on 2 April.
• By
Results from a single-arm study cannot support representations on overall survival, progression-free survival and disease control rate for the cancer drug, the Office of Prescription Drug Promotion said in another “untitled” letter implicating the agency’s CFL guidance.